Literature DB >> 24237632

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Brenda E Porter1, Catherine Jacobson.   

Abstract

Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child's seizures. Nineteen responses met the following inclusion criteria for the study: a diagnosis of epilepsy and current use of cannabidiol-enriched cannabis. Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox-Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child's seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25-60% seizure reduction. Other beneficial effects included increased alertness, better mood, and improved sleep. Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy. Because of the increasing number of states that allow access to medical cannabis, its use will likely be a growing concern for the epilepsy community. Safety and tolerability data for cannabidiol-enriched cannabis use among children are not available. Objective measurements of a standardized preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.
© 2013.

Entities:  

Keywords:  Cannabidiol; Dravet syndrome; Epilepsy; Intractable; Medically refractory seizures; Pediatric; Side effects; Treatment-resistant

Mesh:

Substances:

Year:  2013        PMID: 24237632      PMCID: PMC4157067          DOI: 10.1016/j.yebeh.2013.08.037

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  23 in total

1.  The anticonvulsant activity of cannabinoids in seizure sensitive gerbils.

Authors:  B Cox; M ten Ham; W J Loskota; P Lomax
Journal:  Proc West Pharmacol Soc       Date:  1975

Review 2.  Toward drugs derived from cannabis.

Authors:  R Mechoulam; E A Carlini
Journal:  Naturwissenschaften       Date:  1978-04

3.  Anticonvulsant effect of cannabidiol.

Authors:  F R Ames; S Cridland
Journal:  S Afr Med J       Date:  1986-01-04

4.  Letter: The effect of cannabidiol on maximal electroshock seizures in rats.

Authors:  I Izquierdo; M Tannhauser
Journal:  J Pharm Pharmacol       Date:  1973-11       Impact factor: 3.765

5.  Intractable epilepsy: A survey of patients and caregivers.

Authors:  James W Wheless
Journal:  Epilepsy Behav       Date:  2006-05-03       Impact factor: 2.937

6.  Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.

Authors:  P Consroe; M A Benedito; J R Leite; E A Carlini; R Mechoulam
Journal:  Eur J Pharmacol       Date:  1982-09-24       Impact factor: 4.432

Review 7.  Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Authors:  Antonio Waldo Zuardi
Journal:  Braz J Psychiatry       Date:  2008-09       Impact factor: 2.697

8.  Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat.

Authors:  S A Turkanis; R Karler
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

Authors:  J M Cunha; E A Carlini; A E Pereira; O L Ramos; C Pimentel; R Gagliardi; W L Sanvito; N Lander; R Mechoulam
Journal:  Pharmacology       Date:  1980       Impact factor: 2.547

10.  Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice.

Authors:  R Karler; S A Turkanis
Journal:  Br J Pharmacol       Date:  1980-03       Impact factor: 8.739

View more
  88 in total

1.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 2.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

3.  Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.

Authors:  Evan C Rosenberg; Jay Louik; Erin Conway; Orrin Devinsky; Daniel Friedman
Journal:  Epilepsia       Date:  2017-06-15       Impact factor: 5.864

4.  Medical Marijuana for Epilepsy?

Authors:  Murali K Kolikonda; Kavitha Srinivasan; Manasa Enja; Vishwanath Sagi; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2016-04-01

Review 5.  Cannabinoids in Pediatrics.

Authors:  Christopher T Campbell; Marjorie Shaw Phillips; Kalen Manasco
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

6.  Considerations for clinical trials to study cannabinoids in Canadian children with neurologic disorders.

Authors:  Lauren E Kelly; Anne Junker
Journal:  CMAJ       Date:  2018-08-27       Impact factor: 8.262

7.  Fetal cannabinoid receptors and the "dis-joint-ed" brain.

Authors:  Luigia Cristino; Vincenzo Di Marzo
Journal:  EMBO J       Date:  2014-03-14       Impact factor: 11.598

Review 8.  Marijuana Use in Epilepsy: The Myth and the Reality.

Authors:  Kamil Detyniecki; Lawrence Hirsch
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 9.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.